Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price represents a ...

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

Funds managed by GHO Capital Partners LLP and Ampersand Management LLC agreed to acquire the company, and it will continue to ...

Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move ...

We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

Ampersand Biosciences and Trudeau Institute have been awarded more than $1 million to study infectious diseases.